THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) (a) Department of Chemicals & Petro-Chemicals administers Drugs (Prices Control) Order. However, representatives of BICP is also associated with the Committee.

(b) No, Sir.

(c) Does not arise.

Price of Isoxuprine range formulations

3283. SHRI JASWANT SINGH:
SHRI JAGESH DESAI:

Will the Minister of INDUSTRY be pleased to state:

(a) what is the sales turnover of Isoxuprine, Flucionolone Acetonide, Polymixin Glipizide, Phenformin Hcl and Chlorpropamide as per ORG which is subscribed from out of Government funds during 1986 and 1987;

(b) whether it is a fact that more than 80 per cent of the production and distribution of these drugs is controlled by one or two companies;

(c) if so, by when price control on these products would be imposed;

(d) what were the approved prices of leading brands of these products under DPCO, 1979 and at present; and

(e) whether it is a fact that their prices have substantially gone up?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Retail store audit report ORG does not give sales turnover and provides only All India Estimates of Retail Sales of Pharmaceuticals through the trade channel covering around 175 Companies and these estimates are based on purchase records maintained by 650 retail chemists spread out all over India. The retails sales estimates given in this report represent the purchases made by retail chemists alone, off-take of pharmaceuticals by non retail chemists are not covered in this report.

(b) No, Sir.

(c) Does not arise.

(d) The required details are quite voluminous and are not readily available. The time and efforts required for collecting the same will not be commensurate which the results likely to be achieved.

(e) As per the provision of DPCO, 1987 the manufacturers of non-scheduled medicines are free to revise the prices.

TA/DA expenditure of IDPL and HAL Directors

3284. SHRI JASWANT SINGH:
SHRI JAGESH DESAI:

Will the Minister of INDUSTRY be pleased to state:

(a) what amount has been spent by IDPL and HAL on the TA/DA of the Board of Directors during the last two years; and

(b) what amount has been spent on each of the Government Directors and what facilities were extended to such Directors during the above period?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The requisite information is being collected and will be laid on the Table of the House.

Use of cars by Bengal Immunity

3285. SHRI JASWANT SINGH:
SHRI JAGESH DESAI:

Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Bengal Immunity's bill on use of cars in Delhi is very high as such cars are offered to Government officers; and

(b) what was the expenditure of this Company on cars and other conveyance in Delhi during the last two years;

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) (a) No, Sir.

(b) Expenditure for 1987-88 in Delhi was Rs. 19,550/- as against Rs. 33,350/- for 1986-87.

Liability on account of unintended benefit

3286. SHRI JASWANT SINGH:

SHRI JAGESH DESAI:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 641 given in the Rajya Sabha on the 2nd May, 1988 and state:

(a) what are the basis of arriving at the liability of Pifizer at Rs. 99.08 lakhs originally and subsequently revising it to Rs. 48.21 lakhs;

(b) what were the drugs involved and what was the liability in respect of bulk and formulations separately;

(c) what were the names of the formulations which were ignored for the purpose of determining the liability and what were the reasons for such exclusion;

(d) what was the production of each salt of Oxytetracycline and PAS Sodium and other salts separately from the date of filling the writ upto 31-12-83; and

(e) what were the notified prices and the prices availed by the company during the period?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The liability of M/s Pfizer Ltd., was revised to Rs. 48.21 lakhs by the special team taking into account the under charged prices by the company during April-Nov. 1981.

(b) to (e) The details of drugs of its formulations, its production etc. are quite voluminous. The time and efforts required for collection of these details will not be commensurate with the results likely to be achieved.

Sub committee on identification of drugs in category II

@3287. SHRI B. SATYANARAYAN REDDY:

SHRI DAYANAND SAHAY:

Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 56 given in the Rajya Sabha on the 27th July, 1988 and state:

(a) whether it is a fact that for the purpose of identifying category II drugs a separate committee was constituted and that recommendations of Ministry of Health and Family Welfare were not sought on the essentiality of the drugs in list II;

(b) whether it is a fact that list of category II drugs, drawn up by the Kelkar Committee abounds in non-essential drugs and also drugs which have marginal sale; and

(c) whether the Ministry of Health and Family Welfare propose to review the conduct of the Officers connected with sending recommendations in respect of category II drugs and shifting of category I to category II and withdraw the recommendations?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) For the purpose of identifying category II drugs a Committee was constituted and the Committee included 2 representatives of the Ministry of Health & Family Welfare.

(b) No, Sir.

(c) Information shall be collected from the Ministry of Health and laid on the Table of the House.

Price control on Isoxuprine HCL range formulations

3288. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 661 given in the Rajya Sabha on the 2nd May, 1988 and state:

@Previously unstarred question 2724, transferred from the 17th August, 1988.